MAPT and Alzheimer disease: In an AD mouse model, nicotinamide riboside therapy reduced phosphorylation of tau and enhanced synaptic and cognitive function, which was demonstrated to be facilitated by induction of mitophagy (Hou et al., 2018, 2019).